

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
David N. Herndon *et al.*

Serial No.: 10/025,274

Filed: December 19, 2001

For: METHODS TO ENHANCE WOUND
HEALING AND ENHANCED WOUND
COVERAGE MATERIAL

Group Art Unit: 1633

Examiner: Marvich, Maria


Atty. Dkt. No.: CLFR:184USD1

Confirmation No.: 5877

CERTIFICATE OF ELECTRONIC TRANSMISSION
37 C.F.R. § 1.8

I hereby certify that this correspondence is being
electronically filed with the United States Patent and
Trademark Office via EFS-Web on the date below:

February 8, 2007
Date


Charles P. Landrum

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This application is a divisional application of Serial No. 09/602,183, filed June 22, 2000 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) only copies of those documents not previously cited and submitted to the Patent and Trademark Office in prior application Serial No. 09/602,183 are enclosed for the convenience of the Examiner.

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed. If an appropriate payment has not been enclosed, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/CLFR:184USD1.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Charles P. Landrum
Reg. No. 46,855
Agent for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: February 8, 2007

Form PTO-1449 (modified)		Atty. Docket No. CLFR:184USD1	Serial No. 10/025,274
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant David N. Herndon <i>et al.</i>	
		Filing Date: December 19, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-5</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,002,071	03/26/91	Harrell	128	897	09/27/89
	A2	5,064,655	11/12/91	Uster <i>et al.</i>	424	450	05/23/89
	A3	5,256,644	10/26/93	Antoniades <i>et al.</i>	514	12	03/25/92
	A4	5,651,982	07/29/97	Marx	424	450	06/06/95
	A5	5,728,546	03/17/98	Greene <i>et al.</i>	435	69.1	06/05/95
	A6	5,962,427	10/05/99	Goldstein <i>et al.</i>	514	44	04/12/96
	A7	6,060,590	05/09/00	Bryant <i>et al.</i>	530	399	03/31/98
	A8	6,132,765	10/17/00	DiCosmo <i>et al.</i>	424	450	04/15/97
	A9	6,153,631	11/28/00	Petrie <i>et al.</i>	514	367	02/26/97

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B1	WO 97/07824	03/06/97	WIPO	Japanese (English Abstract)

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Aramaki <i>et al.</i> , "Inhibitory effects of negatively charged liposomes on nitric oxide production from macrophages stimulated by LPS," <i>Biochem. Biophys. Res. Com.</i> , 220:1-6, 1996.
	C2	Aramaki <i>et al.</i> , "Negatively charged liposomes inhibit tyrosine phosphorylation of 41-kDa protein in murine macrophages stimulated with LPS," <i>Biochem. Biophys. Res. Com.</i> , 231:827-830, 1997.
	C3	Bondy <i>et al.</i> , "Clinical uses of insulin-like growth factor I," <i>Ann. Int. Med.</i> , 120:593-601, 1994.
	C4	Branski <i>et al.</i> , "Gene therapy in wound healing: present status and future directions," <i>Gene Therapy</i> , 14:1-10, 2007.

25724007.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:184USD1	Serial No. 10/025,274
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant David N. Herndon <i>et al.</i>	
		Filing Date: December 19, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-5</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C5	Caplen <i>et al.</i> , "Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis," <i>Nat. Med.</i> , 1:39-46, 1995.
	C6	Chrysopoulo <i>et al.</i> , "Growth hormone attenuates tumor necrosis factor alpha in burned children," <i>Arch. Surg.</i> , 134:283-286, 1999.
	C7	Felgner, "Improvements in cationic liposomes for in vivo gene transfer," <i>Human Gene Therapy</i> , 7:1791-1793, 1996.
	C8	Filion and Philips, "Anti-inflammatory activity of cationic lipids," <i>Br. J. Pharmacol.</i> , 122:551-557, 1997.
	C9	Gilpin <i>et al.</i> , "Regulation of the acute phase response genes alpha1-acid glycoprotein and alpha1-antitrypsin correlates with sensitivity to thermal injury," <i>Surgery</i> , 119:664-673, 1996.
	C10	Gore <i>et al.</i> , "Effect of exogenous growth hormone on whole-body and isolated-limb protein kinetics in burned patients," <i>Arch. Surg.</i> , 126:38-43, 1991.
	C11	Guler <i>et al.</i> , "Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats," <i>Proc. Natl. Acad. Sci. USA</i> , 85:4889-4893, 1988.
	C12	Herndon <i>et al.</i> , "A Comparison of Conservative Versus Early Excision," <i>Ann. Surg.</i> , 209:547-553, 1989.
	C13	Herndon <i>et al.</i> , "Effects of Recombinant Human Growth Hormone on Donor-site in Severely Burned Children," <i>Ann. Surg.</i> , 212:424-431, 1990.
	C14	Hettich <i>et al.</i> , "The immunogenicity of glycerol-preserved donor skin," <i>Burns</i> , 20:S71-76, 1994.
	C15	Jabri <i>et al.</i> , "Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients," <i>Diabetes</i> , 43:369-374, 1994.
	C16	Jeschke <i>et al.</i> , "Attenuation of the acute-phase response in thermally injured rats by cholesterol-containing cationic liposomes used as a delivery system for gene therapy," <i>Arch. Surg.</i> , 134:1098-1102, 1999.
	C17	Jeschke <i>et al.</i> , "Biodistribution and feasibility of non-viral IGF-I gene transfers in thermally injured skin," <i>Lab Invest.</i> , 80:151-158, 2000.

25724007.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. CLFR:184USD1	Serial No. 10/025,274
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant David N. Herndon <i>et al.</i>	
	Filing Date: December 19, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-5</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C18	Jeschke <i>et al.</i> , "Effect of multiple gene transfers of insulinlike growth factor I complementary DNA gene constructs in rats after thermal injury," <i>Arch Surg.</i> , 134:1137-1141, 1999.
	C19	Jeschke <i>et al.</i> , "Exogenous liposomal IGF-I cDNA gene transfer leads to endogenous cellular and physiological responses in an acute wound," <i>Am. J. Physiol. Regul. Integr. Comp. Physiol.</i> , 286:R958-966, 2004.
	C20	Jeschke <i>et al.</i> , "IGF-I gene transfer in thermally injured rats," <i>Gene Therapy</i> , 6:1015-1020, 1999.
	C21	Jeschke <i>et al.</i> , "Interaction of exogenous liposomal insulin-like growth factor-I cDNA gene transfer with growth factors on collagen expression in acute wounds," <i>Wound Repair Regen.</i> , 13:269-277, 2005.
	C22	Jeschke <i>et al.</i> , "Non-viral liposomal keratinocyte growth factor (KGF) cDNA gene transfer improves dermal and epidermal regeneration through stimulation of epithelial and mesenchymal factors," <i>Gene Therapy</i> , 9:1065-1074, 2002.
	C23	Jeschke <i>et al.</i> , "Possibilities of non-viral gene transfer to improve cutaneous wound healing," <i>Current Gene Therapy</i> , 1:267-278, 2001.
	C24	Jeschke <i>et al.</i> , "The structure and composition of liposomes can affect skin regeneration, morphology and growth factor expression in acute wounds," <i>Gene Therapy</i> , 12:1718-1724, 2005.
	C25	Jeschke <i>et al.</i> , "Therapeutic success and efficacy of nonviral liposomal cDNA gene transfer to the skin in vivo is dose dependent," <i>Gene Therapy</i> , 8:1777-1784, 2001.
	C26	Jescke, "Mechanisms and possibilities of liposomal gene transfer to affect dermal and epidermal regeneration using the IGF-I cDNA construct," <i>Gene Therapy and Mol. Biol.</i> , 8:201-212, 2004.
	C27	Lo <i>et al.</i> , "Simultaneous treatment with IGF-I and GH additively increases anabolism in parenterally fed rats," <i>Am. J. Physiol.</i> , 269:E368-E376, 1995.
	C28	Martin, "Wound Healing- Aiming for Perfect Skin Regeneration," <i>Science</i> , 276:75-81, 1997.
	C29	Meyer <i>et al.</i> , "Combined insulin-like growth factor-1 and growth hormone improves weight loss and wound healing in burned rats," <i>J. Trauma</i> , 41:1008-1012, 1996.

25724007.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:184USD1	Serial No. 10/025,274
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant David N. Herndon <i>et al.</i>	
		Filing Date: December 19, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-5</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C30	Mulsch <i>et al.</i> , "Diethyldithiocarbamate inhibits induction of macrophage NO synthase," <i>FEBS Lett.</i> , 321:215-218, 1993.
	C31	Mulsch <i>et al.</i> , "Formation and release of dinitrosyl iron complexes by endothelial cells," <i>Biochem. Biophys. Res. Com.</i> , 196:1303-1308, 1993.
	C32	Noguchi <i>et al.</i> , "Membrane fusion plays an important role in gene transfection mediated by cationic liposomes," <i>FEBS Lett.</i> , 433:169-173, 1998.
	C33	Pereira <i>et al.</i> , "Immunohistochemical staining of transgenic beta-galactosidase in burned skin is a better indicator of transfection efficiency than histochemical techniques," <i>J. Immun. Methods</i> , 315:75-79, 2006.
	C34	Pierre <i>et al.</i> , "Insulin-like Growth Factor-I Liposomal Gene Transfer and Systemic Growth Hormone Stimulate Wound Healing," <i>J. Burn Care Rehab</i> , 18:287-291, 1997.
	C35	Richters <i>et al.</i> , "Immunogenicity of glycerol-preserved human cadaver skin in vitro," <i>J. Burn Care Rehabil.</i> , 18:228-233, 1997.
	C36	Rodriguez <i>et al.</i> , "Correlation of the local and systemic cytokine response with clinical outcome following thermal injury," <i>J. Trauma</i> , 34:684-694, 1993.
	C37	Sambrano and Steinberg, "Recognition of oxidatively damaged and apoptotic cells by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages: role of membrane phosphatidylserine," <i>Proc. Natl. Acad. Sci. USA</i> , 92:1396-1400, 1995.
	C38	Shackelford <i>et al.</i> , "Oxidized low density lipoprotein suppresses activation of NF kappa B in macrophages via a pertussis toxin-sensitive signaling mechanism," <i>J. Biol. Chem.</i> , 270:3745-3748, 1995.
	C39	Steenfos, "Growth Factors and Wound Healing," <i>Scand. J. Plast. Reconstr. Hand Surg.</i> , 28:95-105, 1994.
	C40	van Baare <i>et al.</i> , "Virucidal effect of glycerol as used in donor skin preservation," <i>Burns</i> , 20:S77-80, 1994.
	C41	Verma <i>et al.</i> , <i>Nature</i> , 389:239-242, 1997.
	C42	Walker <i>et al.</i> , "Effects of the infusion of insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron dwarfism)," <i>N. Engl. J. Med.</i> , 324:1483-1488, 1991.

25724007.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:184USD1	Serial No. 10/025,274
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant David N. Herndon <i>et al.</i>	
		Filing Date: December 19, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-5</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C43	Zaizen <i>et al.</i> , "The Effect of Perioperative Exogenous Growth Hormone on Wound Bursting Strength in Normal and Malnourished Rats," <i>J. Ped. Surg.</i> , 25:70-74, 1990.

25724007.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.